(HealthDay News) — For patients with chronic heart failure, hemodynamic monitoring with the CardioMEMS-HF system improves the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score more than standard care, according to a study published online in The Lancet to coincide with the European Society of Cardiology Heart Failure 2023, held from May 20 to 23 in Prague.
Jasper J. Brugts, MD, from Erasmus MC University Medical Center in Rotterdam, Netherlands, and colleagues randomly assigned 348 patients with chronic heart failure of New York Heart Association class III and a previous heart failure hospitalization to hemodynamic monitoring (CardioMEMS-HF system) or standard care (176 and 172, respectively). The mean difference in the KCCQ overall summary score at 12 months was measured as the primary end point.
The researchers found that the between-group difference in mean change in KCCQ overall summary score at 12 months was 7.13 (+7.05 and −0.08 in the CardioMEMS and standard care groups, respectively). In the responder analysis, the odds ratios were 1.69 for an improvement of at least 5 points in the KCCQ overall summary score and 0.45 for a deterioration of at least 5 points in the CardioMEMS-HF versus standard care groups. The freedom of device-related or system-related complications was 97.7% and freedom of sensor failure was 98.8%.
“Hemodynamic monitoring and subsequent individualized modification of diuretics and guideline-directed medical therapy substantially and significantly improve quality of life and reduce the number of heart failure hospitalizations among patients with chronic heart failure,” the authors write.
Several authors disclosed ties to pharmaceutical companies, including Abbott Laboratories, which partially funded the study and developed the CardioMEMS-HF system.